Form 8-K - Current report:
SEC Accession No. 0001213900-24-055919
Filing Date
2024-06-26
Accepted
2024-06-26 08:00:10
Documents
15
Period of Report
2024-06-25
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea020849301-8k_allarity.htm   iXBRL 8-K 24138
2 PRESS RELEASE, DATED JUNE 25, 2024 ea020849301ex99-1_allarity.htm EX-99.1 20126
3 GRAPHIC image_001.jpg GRAPHIC 3032
  Complete submission text file 0001213900-24-055919.txt   235958

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE allr-20240625.xsd EX-101.SCH 3051
5 XBRL LABEL FILE allr-20240625_lab.xml EX-101.LAB 34916
6 XBRL PRESENTATION FILE allr-20240625_pre.xml EX-101.PRE 22813
18 EXTRACTED XBRL INSTANCE DOCUMENT ea020849301-8k_allarity_htm.xml XML 3968
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 241070643
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)